Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates

Clinical and Vaccine Immunology

Volumn 18, Issue 3, 2011, Pages 483-486

  Kimura, Alan ^a   Toneatto, Daniela ^a   Kleinschmidt, Annett ^a   Wang, Huajun ^a   Dull, Peter ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOLOGICAL MONITORING; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG DOSE SEQUENCE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION PREVENTION; INFECTION RISK; INJECTION SITE INDURATION; INJECTION SITE REACTION; LABORATORY PERSONNEL; MALAISE; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NORMAL HUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHINITIS; RHINOPHARYNGITIS; RISK ASSESSMENT; SERUM BACTERICIDAL ACTIVITY; SINGLE DRUG DOSE; SYSTEMIC DISEASE; TREATMENT DURATION; VACCINATION REACTION; WORK ENVIRONMENT;

ADOLESCENT; ADULT; BLOOD BACTERICIDAL ACTIVITY; FEMALE; HUMAN EXPERIMENTATION; HUMANS; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS; OCCUPATIONAL DISEASES; VACCINES, COMBINED; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 79952539379     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00304-10     Document Type: Article

References (19)

1. Balmer, P., et al. 2004. Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals. Infect. Immun. 72:332-337.
2. Bambini, S., et al. 2009. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27:2794-2803.
3. Borrow, R., et al. 2006. Neisseria meningitidis group B correlates of protection and assay standardization - international meeting report, Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 24:5093-5107. (Pubitemid 44209069)
4. Boutet, R., J. M. Stuart, D. M. Jones, and E. B. Kaczmarski. 2001. Prevention of meningococcal infection in laboratory workers - an audit of practice in England and Wales. Commun. Dis. Public Health 4:130-132.
5. Centers for Disease Control and Prevention. 2002. Laboratory-acquired meningococcal disease - United States, 2000. JAMA 287:1256-1258.
6. Centers for Disease Control and Prevention. 2009 Sep 25. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb. Mortal. Wkly. Rep. 58:1042-1043.
7. Cohn, A. C., et al. 2010. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin. Infect. Dis. 50:184-191.
8. Donnelly, J., et al. 2010 Nov 9. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc. Natl. Acad. Sci. U. S. A. 107:19490-19495.
9. Findlow, J., et al. 2010. Multicentre, open-label, randomised phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin. Infect. Dis. 51:1127-1137.
10. Giuliani, M. M., et al. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839.
11. Giuliani, M. M., et al. 2010. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 28:5023-5030.
12. National Advisory Committee on Immunization. 2009. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee statement (ACS). Can. Commun. Dis. Rep. 35(ACS-3):1-40.
13. Nøkleby, H, et al. 2007. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine 25:3080-3084. (Pubitemid 46505045)
14. Platonov, A. E., I. V. Vershinina, E. J. Kuijper, R. Borrow, and H. Käyhty. 2003. Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. Vaccine 21:4437-4447. (Pubitemid 37130282)
15. Reisinger, K. S., et al. 2009. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin. Vaccine Immunol. 16:1810-1815.
16. Santos, G. F., et al. 2009. Investigation on the effect of immune selection on resistance to bactericidal antibodies to group B meningococci in vitro. Clin. Vaccine Immunol. 16:1693-1695.
17. Siberry, G. K., et al. 2010. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. Pediatr. Infect. Dis. J. 29:391-396.
18. Snape, M. D., et al. 2010. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr. Infect. Dis. J. 29:e71-e79.
19. Snape, M. D., et al. 2008. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299:173-184.